The Role of IL5 in Epithelial Cell Integrity
Chronic Rhinosinusitis With Nasal Polyps, Chronic Rhinosinusitis (Diagnosis)
About this trial
This is an interventional basic science trial for Chronic Rhinosinusitis With Nasal Polyps
Eligibility Criteria
Inclusion Criteria: (1) sinonasal inflammation for greater than 12 weeks which include at least 2 of the following symptoms: nasal obstruction/congestion, nasal discharge (anterior or posterior), facial pressure/pain, reduction of sense of smell. (2) confirmation of the clinical symptoms by: (2a) CT scan evidence of paranasal sinus mucosal inflammation, and/or (2b) endoscopic exam evidence of purulence from the sinuses or ostiomeatal complex; and (3) presence of nasal polyps seen on endoscopic exam or sinus CT scan. Exclusion Criteria: 1. Children under the age of 18 will be excluded due to: possible confounding diagnosis of cystic fibrosis and other non-Type 2 inflammatory etiologies that commonly presents with nasal polyps in the pediatric population. lack of complete pneumatization of the majority of paranasal sinuses 2. pregnant or lactating females, 3. prisoners, 4. mentally disabled 5. persons unable to give informed consent will be contemplated for inclusion. 6. disease secondary to a clearly defined anatomic process, such as facial trauma, and obstruction due to sinonasal neoplasm. 7. exposure to oral or systemic IV glucocorticoids within 2 weeks of surgery 8. exposure to immunomodulatory biologics will be excluded. These include, but are not limited to systemic treatment with biologics omalizumab, dupilumab, mepolizumab, benralizumab, reslizumab, or rituximab.
Sites / Locations
- Johns Hopkins Bayview Medical CenterRecruiting
- Johns Hopkins HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Mepolizumab treatment arm
Control arm
Nasal epithelial cells will be exposed in vitro to mepolizumab in culture.
Nasal epithelial cells will be exposed in vitro to media without mepolizumab in culture